Over the last decade, research to slow or reverse the aging process has accelerated, giving rise to a dynamic field of medicine. This ambitious branch of science is driving the development of novel approaches to extend the human “health span” and delay the onset of age-related disease by focusing on causal mechanisms, rather than symptoms.
At Okyanos, we are pleased to offer an exclusive immune restoration therapy, developed by researchers at Rejenevie™ Therapeutics, to potentially unlock, restore and strengthen the power of the aging immune system. Based on the science of parabiosis, this proprietary, first-in-world clinical protocol harnesses the restorative ability of young blood stem and immune cells to improve stem and immune cell function in aging populations.
Researchers thoroughly tested the approach for more than five years to prove the therapy was safe and effective in animal models. In early 2017, Rejenevie submitted an application to treat humans to the Bahamian National Stem Cell Ethics Committee. Within a year, approval was granted.
The first Rejenevie patient was treated on December 15, 2017, at The Okyanos Center for Regenerative Medicine in Freeport, Bahamas, where Rejenevie’s cGMP-certified laboratory is located. In total, five patients participated in the Phase I clinical trial that was completed in February 2019.
Recently, a Phase II clinical trial has been approved and initiated to treat an additional 20 patients to further study the safety and efficacy of the treatment.
For more on the 10 Steps to immune restoration, view infographic below.
Initial results are promising. Natural killer cell function, a measure of the immune system’s ability to fight and kill cancer cells, has increased in the majority of patients participating in the Phase I clinical trial. Rejenevie’s data also reveals an increase in the ratio of infection- and cancer-fighting lymphoid cells compared to the pro-inflammatory myeloid immune cells.
Finally, and most impressively, a dramatic decrease in the number of aging- and senescence-related genes expressed in the circulating immune cells of patients has been observed.
The clinical program follows rigorous guidelines to ensure patient safety and the highest quality point-of-care. The ideal candidate for the Rejenevie™ immune restoration therapy is a person age 55 or older, in good general health and no history of blood-borne cancer. The candidate will have peripheral blood collected prior to stem cell mobilization for baseline CBC, immune cell phenotyping and stimulation response. After initial infusion, patients are evaluated at 1, 3, 6, 9 and 12 months. Patients who respond to treatment and experience improved immune function during follow-up monitoring will be re-assessed at 12 months post-treatment to determine restoration stability or regression.
For more on the clinical research behind Rejenevie, go to www.rejenevie.com/clinical-program/.
For more information, please visit: www.rejenevie.com